According to Fortune Business Insights, the global women health diagnostics market size was valued at USD 27.07 billion in 2025 and is projected to grow from USD 28.77 billion in 2026 to USD 47.66 billion by 2034, exhibiting a CAGR of 6.5% during the forecast period from 2026 to 2034. North America dominated the market in 2025, accounting for a 34.65% share.
The women health diagnostics market is evolving as healthcare providers and patients increasingly emphasize early detection and preventive care. Routine cervical cancer screening, breast imaging, STI testing, fertility diagnostics, pregnancy testing, and osteoporosis assessments represent important areas of demand.
The increasing incidence of conditions such as cancer, osteoporosis, infertility, and infectious diseases is further supporting the need for diagnostic tests and devices. At the same time, healthcare providers are adopting automated and connected diagnostic technologies to improve testing efficiency and turnaround times.
For detailed market insights: https://www.fortunebusinessinsights.com/women-s-health-diagnostics-market-111885
Artificial intelligence (AI) is emerging as a significant trend in women's imaging. Breast diagnostics are increasingly incorporating AI for detection, breast-density assessment, triage, and workflow optimization. Healthcare systems are looking for technologies that can improve diagnostic efficiency and provide more consistent results.
For example, in November 2024, GE HealthCare and RadNet's DeepHealth announced a collaboration to develop SmartTechnology AI solutions for imaging. The initiative began with the integration of DeepHealth's SmartMammo with GE HealthCare's Senographe Pristina mammography system to improve breast cancer screening efficiency and accuracy.
The adoption of AI-enabled imaging can enhance radiologists' efficiency, potentially reduce unnecessary biopsies, and support demand for advanced diagnostic equipment.
The expansion of women's health test kits is a major factor driving market growth. More women are undergoing routine cervical cancer screening, breast imaging, and STI testing due to public health initiatives, updated guidelines, and increased payer coverage.
The increasing incidence of cancer, osteoporosis, and infertility is also generating demand for diagnostic test kits and devices, including follow-up diagnostic procedures. For instance, the source notes that approximately 316,950 women in the U.S. were projected to receive a diagnosis of invasive breast cancer in 2025, along with 59,080 cases of non-invasive breast cancer.
However, reimbursement gaps and affordability challenges can limit adoption of advanced diagnostics, particularly in lower-resource settings. Competition for healthcare budgets and limited government initiatives for certain tests can further restrict market penetration.
Based on product, the market is segmented into diagnostic devices, diagnostic test kits, and standalone consumables & reagents.
The diagnostic devices segment accounted for the largest market share in 2025. These devices form an important part of hospital and laboratory infrastructure and support high-throughput women's health testing. Automation, faster turnaround times, and connectivity are encouraging upgrades to diagnostic equipment.
Meanwhile, the diagnostic test kits segment is projected to grow at a CAGR of 7.1% during the forecast period.